• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

FDA Approves Sanofi and AstraZeneca’s RSV Antibody for Newborns, Infants

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jul 17, 2023 at 07:12: PM
via On Monday, the FDA announced approval of Sanofi and AstraZeneca’s monoclonal antibody drug Beyfortus (nirsevimab) for the preventative treatment of respiratory syncytial virus in infants entering their first season of RSV, and children up to 24 months old at severe risk of RSV infection entering their second RSV season.

article source
 

<



Similar threads

cafead
FDA Approves Regeneron-Sanofi&#039;s Sarilumab As First Biologic For Stiffness, Pain In Muscles
Replies
0
Views
240
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA approves Sanofi’s long-lasting hemophilia drug
Replies
0
Views
254
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA approves Sanofi and Regeneron’s Dupixent to treat prurigo nodularis
Replies
0
Views
192
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA approves Sanofi and Regeneron’s Dupixent for atopic dermatitis in young children
Replies
0
Views
152
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA approves Sanofi&#039;s monoclonal antibody treatment for CAD
Replies
0
Views
115
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote